Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684344 | 0.86 | MALT1 (0.48) | MALT1KDM4EKCNMA1 | |
| SCHEMBL2425939 | 0.85 | MALT1 (0.64) | MALT1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4533155 | 0.84 | MALT1 (0.54) | MALT1KDM4EKCNMA1KMT2AMEN1 | |
| SCHEMBL4879872 | 0.83 | KDM4E (0.60) | MALT1KDM4EKMT2ARECQL | |
| SCHEMBL24377504 | 0.82 | MALT1 (0.57) | MALT1KDM4ERECQL | |
| SCHEMBL4103009 | 0.80 | MAPT (0.68) | MALT1SMN1; SMN2 | |
| SCHEMBL1728915 | 0.80 | KMT2A (0.50) | MALT1KDM4EKMT2AMEN1RECQL | |
| SCHEMBL24377347 | 0.80 | SMN1; SMN2 (0.49) | MALT1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27703256 | 0.79 | MALT1 (0.51) | MALT1KMT2A | |
| SCHEMBL18255216 | 0.79 | KDM4E (0.66) | KDM4EKCNMA1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2022086920-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| CN-101151239-A | Novel biaromatic compounds, inhibitors of the P2X7-receptor | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
| CN-101052625-A | As P2X7Adamantyl derivatives of receptor antagonists | ASTRAZENECA AB (SE) | 2007-10-10 | — | — | CN | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382891-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | QPCT, QPCTL, GLUL | MALT1 4344/4885KDM4E 2763/4885KCNMA1 4509/4885 |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | MALT1 3949/4885KDM4E 4115/4885KCNMA1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.